biostudies-literatureCommons RJCapability Systems CentreCenters for Disease Control and PreventionConselho Nacional de Desenvolvimento Científico e TecnológicoNational Health and Medical Research CouncilBill and Melinda Gates FoundationWellcome Trust172-183https://www.ebi.ac.uk/biostudies/studies/S-EPMC7615564biostudies-literatureUnknown24(2)<h4>Background</h4>Primaquine is used to eliminate Plasmodium vivax hypnozoites, but its optimal dosing regimen remains unclear. We undertook a systematic review and individual patient data meta-analysis to investigate the efficacy and tolerability of different primaquine dosing regimens to prevent P vivax recurrence.<h4>Methods</h4>For this systematic review and individual patient data meta-analysis, we searched MEDLINE, Web of Science, Embase, and Cochrane Central for prospective clinical studies of uncomplicated P vivax from endemic countries published between Jan 1, 2000, and June 8, 2023. We included studies if they had active follow-up of at least 28 days, and if they included a treatment group with daily primaquine given over multiple days, where primaquine was commenced within 7 daThe Lancet. Infectious diseasesEffect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis.PMC76155641194702093956/Z/10/Z200909223253/Z/21/Z093956/Z/10/CGreen JAChau NHRijal KRLidia KKarunajeewa Hvon Seidlein LAdhikari BPrice RNNaadim MNTaylor WRJBoyd SCGhimire PLadeia-Andrade SBaird JKDegaga TSNosten FMueller IZuluaga-Idarraga LMAbreha TAnstey NMLongley RJVieira JLFAwab GRWatson JAChu CSGonzalez-Ceron LGuerin PJWoyessa AThanh PVErhart AAssefa AWorldWide Antimalarial Resistance Network (WWARN) Vivax Primaquine Dosing Efficacy, Tolerability and Safety Study GroupSimpson JABarber BEGrigg MJLlanos-Cuentas AKoh GCPereira DBFerreira MUDondorp AMCui LCommons RJThriemer KWilliam THwang JLacerda MVGDaher APasaribu APPrice DJDay NPRajasekhar MWoodrow CJSutanto IMekuria AHPukrittayakamee SNelwan EJEdler PSattabongkot JStepniewska KWhite NJfalseEffect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis.<h4>Background</h4>Primaquine is used to eliminate Plasmodium vivax hypnozoites, but its optimal dosing regimen remains unclear. We undertook a systematic review and individual patient data meta-analysis to investigate the efficacy and tolerability of different primaquine dosing regimens to prevent P vivax recurrence.<h4>Methods</h4>For this systematic review and individual patient data meta-analysis, we searched MEDLINE, Web of Science, Embase, and Cochrane Central for prospective clinical studies of uncomplicated P vivax from endemic countries published between Jan 1, 2000, and June 8, 2023. We included studies if they had active follow-up of at least 28 days, and if they included a treatment group with daily primaquine given over multiple days, where primaquine was commenced within 7 da2024-01-01T00:00:00Z2024 Feb2026-07-15T04:25:29.348Z2026-07-01T03:06:57.099ZS-EPMC76155643774849610.1016/S1473-3099(23)00430-9